Wednesday, July 23, 2014

WB starts Imprivata at outperform

WB starts Imprivata at outperform

July 21, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Imprivata (NYSE:IMPR) with an “outperform” rating and an “aggressive growth” profile. The stock closed at $16.01 on Friday. “Although Imprivata targets a unique niche in the healthcare information technology space, its total addressable market is quite substantial,” writes analyst Ryan Daniels. “We believe that the company’s worldwide healthcare […]

Avivagen to test dietary fish supplement in Thailand

Avivagen to test dietary fish supplement in Thailand

July 18, 2014 by · Leave a Comment 

Tweet Avivagen (TSX-V:VIV) has entered an agreement with Nam Sai Farms of Thailand to conduct a trial to determine the effects of its OxC-beta on the grow-out parameters of tilapia. The trial will test the effects of two different levels of OxC-beta and a positive control product against a negative control on the grow-out parameters […]

Cynapsus to start Phase 2 trial of APL-130277


Cynapsus to start Phase 2 trial of APL-130277


July 17, 2014 by · Leave a Comment 

Tweet Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be initiated according to a proposal submitted to the FDA under the company’s IND application. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug […]

Venaxis responding to FDA questions on APPY1 Test

Venaxis responding to FDA questions on APPY1 Test

July 16, 2014 by · Leave a Comment 

Tweet The FDA has reviewed Venaxis’ (NASDAQ:APPY) submission to market its APPY1 Test and has provided the company with questions and information requests about the submission. The CE Marked APPY1Test is a multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis. Venaxis is compiling responses […]

Cantor starts Radius Health at buy

Cantor starts Radius Health at buy

July 16, 2014 by · Leave a Comment 

Tweet Cantor Fitzgerald has initiated coverage of Radius Health (NASDAQ:RDUS) with a “buy” rating and $20 price target. The stock closed at $13.05 on Wednesday. “We like the simplicity of the company’s value proposition: a late-stage asset with near-term revenue potential, with the potential to cannibalize a $1-billion product in a market with strong demographic […]

WB starts Tandem Diabetes Care at outperform

WB starts Tandem Diabetes Care at outperform

July 15, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with an “outperform” rating and “aggressive growth” profile. The stock closed at $13.37 on Tuesday. Tandem Diabetes makes and markets a durable, tube-based insulin pump with an easy to train and use touch screen user interface to treat Type 1 and potentially Type 2 […]

HCW starts Transition Therapeutics at buy

HCW starts Transition Therapeutics at buy

July 15, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) with a “buy” rating and 12-month price target of $10. The stock closed at $6.58 on Monday. Transition has two molecules in clinical evaluation in three indications. ELND005 is a small molecule in Phase 2 for Alzheimer’s disease (AD) associated agitation, and Down syndrome […]

Stifel starts Kite Pharma at buy

Stifel starts Kite Pharma at buy

July 15, 2014 by · Leave a Comment 

Tweet Stifel Nicholas has launched coverage of Kite Pharma (NASDAQ:KITE) with a “buy” rating and $31 target price. The stock closed at $24.05 on Monday “We believe that Kite’s lead drug KTE-C19 has the potential to surpass $1-billion in worldwide sales, treating diffuse large B-cell lymphoma (DLBCL),” writes analyst Joel Sendek. He views the 80% […]

Manoj Venkiteshwar joins TearLab as VP of medical affairs

Manoj Venkiteshwar joins TearLab as VP of medical affairs

July 14, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) announced the appointment of Manoj Venkiteshwar to its senior management team in the newly created position of VP of medical affairs. Dr. Venkiteshwar’s mandate will be the development and execution of a comprehensive academic and key opinion leaders (KOL) management strategy for the company. He joins TearLab from his current position as […]

WB ups Vital Therapies price target to $36

WB ups Vital Therapies price target to $36

July 14, 2014 by · Leave a Comment 

Tweet William Blair has raised its price target on “outperform-rated” Vital Therapies (NASDAQ:VTL) to $36 from $28, citing an update on the status of the ELAD clinical program and highlights from investor meetings. The stock closed at $23.52 on Friday “We also revised a few assumptions in our model, the most important being the pricing increase […]

Next Page »

Email Newsletters with Constant Contact
Google+